repurposing
Drug repurposing allows a reconciliation of the time of research with the one of medicine in order to meet the high medical need
Drug screening
Screening of thousand molecules helps in identifying drug candidates for patients and potential new therapeutic targets.
development
The development of approved molecule is facilitated by the available knowledge produced by the former developments.
Apteeus has developed unique know-how and technology dedicated to drug discovery and repositioning. We are interested in pathologies for which the medical need is important and largely unsatisfied, particularly rare monogenic diseases. Our technology allows us to carry out discovery projects in a few months, and to identify new drug candidates. We work in collaboration with patient associations, doctors and academic and industrial partners. Our activity breaks with the classic drug discovery scheme and aims for a rapid and significant social impact.
OUR TECHNOLOGY
Operando®
OPERANDO is the biomedical research program in place for collecting cutaneous biopsies from patients in order to isolate the cells “model” of the pathology.
evidenceFactory®
evidenceFactory is the processes we use to measure, in vitro, the causal defects of the symptoms. Based on cell imaging and mass spectrometry, they are systematically miniaturized and automated to quickly test several thousand molecules.
TEE Library®
TEE Library is our proprietary collection of molecules approved for human use and enriched daily that we test in every new screen.
INNOVATION 2030 CONCOURS MONDIAL D'INNOVATION
NEWS
8.8 million euros for accelerated drug repurposing for rare neurological disorders
APTEEUS has received funding from the frontiers in Research Fund (NFRF) – 2022 Horizon Global…
In 2023, we will again associate empathy and humanity with our discoveries and our achievements. Apteeus wish you the best!
2023 is an important year for Apteeus. Our role as scientific support and our integration…
15th edition of the Rare Disease Day
On the occasion of the 15th edition of the Rare Diseases awareness campaign which took…
LEADERSHIP
Dr. Terence Beghyn
Pharm.D & PhD in Medicinal Chemistry
Passionate about drug discovery technologies, Terence co-founded Apteeus to put his expertise to work for patients with orphan diseases. Terence is President of the company Apteeus.
Professor Benoit DEPREZ
Pharmacien et professeur en Chimie Thérapeutique
Benoit began his career in two biotech companies by leading the chemistry and drug discovery teams. Returning to the University in 2006, he set up a drug discovery laboratory at the Institut Pasteur de Lille, which was labelled by INSERM. Benoit is Scientific Director of the Institut Pasteur de Lille. He co-founded Apteeus and is strategic advisor.
partners
